Senores Pharmaceuticals

Senores Pharmaceuticals Reports 108% PAT Growth in FY26; Eyes Strong FY27 Guidance

Senores Pharmaceuticals reports a 108% profit surge to ₹122 Cr in FY26. Management targets 30-40% revenue growth in FY27 as US ANDA launches accelerate.

Senores Pharmaceuticals · 14 May 2026, 7:24 PM IST